Source Paper
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Joseph F. Cheer, Kate M. Wassum, Michael L. A. V. Heien, Paul E. M. Phillips, R. Mark Wightman
Source Paper
Joseph F. Cheer, Kate M. Wassum, Michael L. A. V. Heien, Paul E. M. Phillips, R. Mark Wightman
Journal of Neuroscience • 2004
Dopaminergic neurotransmission has been highly implicated in the reinforcing properties of many substances of abuse, including marijuana. Cannabinoids activate ventral tegmental area dopaminergic neurons, the main ascending projections of the mesocorticolimbic dopamine system, and change their spiking pattern by increasing the number of impulses in a burst and elevating the frequency of bursts. Although they also increase time-averaged striatal dopamine levels for extended periods of time, little is known about the temporal structure of this change. To elucidate this, fast-scan cyclic voltammetry was used to monitor extracellular dopamine in the nucleus accumbens of freely moving rats with subsecond timescale resolution. Intravenous administration of the central cannabinoid (CB 1 ) receptor agonist, R (+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(1-naphthalenyl) methanone mesylate, dose-dependently produced catalepsy, decreased locomotion, and reduced the amplitude of electrically evoked dopamine release while markedly increasing the frequency of detected (nonstimulated) dopamine concentration transients. The CB 1 receptor antagonist [ N -piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] reversed and prevented all agonist-induced effects but did not show effects on dopamine release when injected alone. These data demonstrate that doses of a cannabinoid agonist known to increase burst firing produce ongoing fluctuations in extracellular dopamine on a previously unrecognized temporal scale in the nucleus accumbens.
Objective: To assess the effects of CB1 receptor agonist administration on catalepsy, locomotion, and dopamine release dynamics in the nucleus accumbens of awake rats using fast-scan cyclic voltammetry
This is a Cannabinoid Agonist Administration and Behavioral Assessment protocol using rat as the model organism. The procedure involves 9 procedural steps, 2 equipment items, 2 materials. Extracted from a 2004 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Surgical implantation and electrode placement • Baseline dopamine monitoring • Intravenous administration of CB1 agonist
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Implant electrodes in the nucleus accumbens of freely moving rats for fast-scan cyclic voltammetry monitoring
Note: Rats must be freely moving to allow behavioral assessment
“monitor extracellular dopamine in the nucleus accumbens of freely moving rats with subsecond timescale resolution”
Establish baseline extracellular dopamine levels and spontaneous dopamine transient frequency in nucleus accumbens
Note: Measure nonstimulated dopamine concentration transients
“monitor extracellular dopamine in the nucleus accumbens of freely moving rats with subsecond timescale resolution”
Administer CB1 receptor agonist intravenously in dose-dependent manner while monitoring behavioral and neurochemical responses
Note: Dose-dependent administration to assess dose-response relationship
“Intravenous administration of the central cannabinoid (CB1) receptor agonist, R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(1-naphthalenyl) methanone mesylate, dose-dependently produced catalepsy”
Measure cataleptic responses following CB1 agonist administration
Note: Catalepsy is a primary behavioral outcome measure
“dose-dependently produced catalepsy, decreased locomotion”
Monitor locomotor activity in freely moving rats following CB1 agonist administration
Note: Decreased locomotion is expected outcome
“decreased locomotion, and reduced the amplitude of electrically evoked dopamine release”
Apply electrical stimulation and measure amplitude of evoked dopamine release using fast-scan cyclic voltammetry
Note: Amplitude is expected to be reduced by CB1 agonist
“reduced the amplitude of electrically evoked dopamine release while markedly increasing the frequency of detected (nonstimulated) dopamine concentration transients”
Monitor frequency of nonstimulated dopamine concentration transients in nucleus accumbens during CB1 agonist effects
Note: Frequency is expected to increase markedly with CB1 agonist
“markedly increasing the frequency of detected (nonstimulated) dopamine concentration transients”
Administer CB1 receptor antagonist to reverse and prevent agonist-induced effects
Note: Antagonist alone does not affect dopamine release
“The CB1 receptor antagonist [N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] reversed and prevented all agonist-induced effects but did not show effects on dopamine release when injected alone”
Continue monitoring dopamine release, catalepsy, and locomotion following CB1 antagonist administration to confirm reversal of agonist effects
Note: Verify complete reversal of all agonist-induced behavioral and neurochemical effects
“reversed and prevented all agonist-induced effects”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
To assess the effects of CB1 receptor agonist administration on catalepsy, locomotion, and dopamine release dynamics in the nucleus accumbens of awake rats using fast-scan cyclic voltammetry
Objective
To assess the effects of CB1 receptor agonist administration on catalepsy, locomotion, and dopamine release dynamics in the nucleus accumbens of awake rats using fast-scan cyclic voltammetry
Subjects
From paperrat • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperFreely moving rats used for monitoring
Surgical implantation and electrode placement (Not specified)
Baseline dopamine monitoring (Not specified)
Intravenous administration of CB1 agonist (Not specified)
Assessment of catalepsy (Not specified)
Catalepsy severity
From paperNot specified in provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Locomotor activity
From paperNot specified in provided text
Artifact type
Longitudinal gait metrics and per-animal performance tables
Comparison focus
Compare recovery trajectory across post-injury timepoints and treatment conditions
Amplitude of electrically evoked dopamine release
From paperNot specified in provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Frequency of spontaneous dopamine concentration transients
From paperNot specified in provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Catalepsy severity
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Locomotor activity
From paperRaw artifact
Per-run gait capture with paw placement, timing, and stride features for each animal
Processed artifact
Cleaned gait metrics table and recovery trend summary across timepoints
Final reported form
Group comparisons of gait indices, stride metrics, or recovery curves
Amplitude of electrically evoked dopamine release
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Frequency of spontaneous dopamine concentration transients
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Not specified in provided text
Scoring or quantification
Quantify the primary readouts for this experiment: Catalepsy severity; Locomotor activity; Amplitude of electrically evoked dopamine release; Frequency of spontaneous dopamine concentration transients.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Catalepsy severity, Locomotor activity, Amplitude of electrically evoked dopamine release, Frequency of spontaneous dopamine concentration transients.
Source links and direct wording from the methods section for validation and deeper review.
Citation
Joseph F. Cheer et al. (2004). Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats. Journal of Neuroscience
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
9
Evidence Quotes
13
Protocol Items
4
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
9
Evidence
13
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work